ArticleEuropean journal of nuclear medicine and molecular imaging2024
Enhanced detection of damaged myocardium and risk stratification in hypertrophic cardiomyopathy using integrated [
Article in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Cardiovascular imaging with total-body PET.The British journal of radiology · 2026Review
- Radiofrequency ablation of atrial flutter with 1:1 accessory pathway conduction improved cardiac function in a patent with PRKAG2 Cardiomyopathy. Insights with 68Ga-FAPI PET/CT imaging.The international journal of cardiovascular imaging · 2026Article
- Article
- Prognostic value of cardiac fibroblast activation heterogeneity assessed by FAPI PET radiomics in hypertrophic cardiomyopathy: a proof-of-concept study.Open heart · 2026Article
- Fibroblast activation protein-targeted PET/CT in multiple non-ischemic cardiomyopathies.European journal of nuclear medicine and molecular imaging · 2025Article
- FAPI-Targeted Molecular Imaging: Transforming Insights into Post-Ischemic Myocardial Remodeling?Molecular diagnosis & therapy · 2025Review
- The Utility of Nuclear Imaging in Hypertrophic Cardiomyopathy: A Narrative Review.Journal of clinical medicine · 2025Review
- Gallium-Labeled PET Radiopharmaceuticals in Cardiovascular Disease.Pharmaceuticals (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeThis study aims to explore the correlation between PET and CMR in integrated [
methodsThis study included 20 HCM patients and 11 age- and gender-matched controls. PET analysis evaluated left ventricular (LV) [
resultThe FAPI uptake, myocardial mass, myocardial thickness, and T1/T2 mapping values were significantly higher in HCM patients compared to controls. Twenty HCM patients and their 320 myocardial segments were discussed. Increased [
conclusion[
Indexed as
Identifiers
39180571What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.